স্লোভানিয়া - স্লোভেনীয় - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

mitomicin - prašek za intravezikalno raztopino/raztopino za injiciranje - mitomicin 1 mg / 1 ml - mitomicin

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - doksorubicinijev klorid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastična sredstva - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

স্লোভানিয়া - স্লোভেনীয় - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

accord healthcare - mitomicin - prašek za raztopino za injiciranje/infundiranje - mitomicin 20 mg / 1 viala - mitomicin

স্লোভানিয়া - স্লোভেনীয় - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

mitomicin - prašek za raztopino za injiciranje/infundiranje - mitomicin 10 mg / 1 viala - mitomicin

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

sanofi b.v. - klofarabin - predkroglomerna limfoblastna levkemija limfoma - antineoplastična sredstva - zdravljenje akutno limfoblastno levkemijo, (vse), pri pediatričnih bolnikih, ki so ponovila ali so ognjevarni po prejemu vsaj dve predhodni režimi in če ni druge možnosti zdravljenja, predvidene za posledico trajno odgovor. varnost in učinkovitost sta bili ocenjeni pri študijah pri bolnikih ≤ 21 let pri začetni diagnozi.

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

pfizer europe ma eeig  - axitinib - karcinom, ledvična celica - proteinska kinaza inhibitorji - inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) after failure of prior treatment with sunitinib or a cytokine.

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

novartis europharm limited - lapatinib - neoplazme dojke - proteinska kinaza inhibitorji - tyverb je indiciran za zdravljenje bolnikov z rakom dojke, katerih tumorji, overexpress her2 (erbb2):v kombinaciji z capecitabine za bolnike z napredovalim ali metastatskim bolezni s napredovanje po predhodnem terapijo, ki mora biti vključeni anthracyclines in taxanes in terapija s trastuzumab v metastatskim nastavitev;v kombinaciji z trastuzumab za bolnike z hormon-receptor-negativne metastatskim bolezen, ki je napredovala na predhodno trastuzumab zdravljenja ali terapije v kombinaciji s kemoterapijo;v kombinaciji z zaviralec aromataze za ženske po menopavzi z hormon-receptor-pozitivno metastatskim bolezni, ki trenutno niso namenjene za kemoterapijo. bolniki v registraciji študija prej niso bili zdravljeni z trastuzumab ali zaviralec aromataze. ni na voljo so podatki o učinkovitosti te kombinacije glede na trastuzumab v kombinaciji z zaviralec aromataze v tem bolnik prebivalstva.

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

cheplapharm arzneimittel gmbh - kapecitabin - colonic neoplasms; breast neoplasms; colorectal neoplasms; stomach neoplasms - antineoplastična sredstva - xeloda je primerna za adjuvant zdravljenje bolnikov po operaciji faze iii (dukes " oder c) rak debelega črevesa. xeloda je primerna za zdravljenje metastatskega raka debelega črevesa in danke. xeloda je določen za prvo linijo zdravljenja naprednih raka želodca v kombinaciji z platinum, ki temelji režim. xeloda v kombinaciji z docetaxel je indiciran za zdravljenje bolnikov z lokalno napredno ali metastatskega raka dojke po okvari citotoksična kemoterapija. predhodno zdravljenje bi moralo vključiti antraciklin. xeloda je prikazano tudi kot monotherapy za zdravljenje bolnikov z lokalno napredno ali metastatskega raka dojke po okvari taxanes in anthracycline-ki vsebujejo kemoterapijo režim ali za koga še anthracycline zdravljenje ni navedeno.

স্লোভানিয়া - স্লোভেনীয় - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

teva pharma b.v. - doksorubicin - prašek za koncentrat za raztopino za infundiranje - doksorubicin 46,75 mg / 1 viala - doksorubicin